Functional DNA Molecules Enable Selective and Stimuli-Responsive Nanoparticles for Biomedical Applications.
Journal
Accounts of chemical research
ISSN: 1520-4898
Titre abrégé: Acc Chem Res
Pays: United States
ID NLM: 0157313
Informations de publication
Date de publication:
17 09 2019
17 09 2019
Historique:
pubmed:
15
8
2019
medline:
12
8
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
Nanoparticles (NPs) have enormous potential to improve disease diagnosis and treatment due to their intrinsic electronic, optical, magnetic, mechanical, and physiological properties. To realize their full potential for nanomedicine, NPs must be biocompatible and targetable toward specific biomolecules to ensure selective sensing, imaging, and drug delivery in complex environments such as living cells, tissues, animals, and human bodies. In this Account, we summarize our efforts to impart specific biocompatibility and biorecognition functionality to NPs by developing strategies to integrate inorganic and organic NPs with functional DNA (fDNA), including aptamers, DNAzymes, and aptazymes to create fDNA-NPs. These hybrid NPs take advantage of fDNA's ability to either bind targets or catalyze reactions in the presence of targets selectively and utilize their unique physicochemical properties including small size, low immunogenicity, and ease of synthesis and chemical modification in comparison with other molecules such as antibodies. By integrating inorganic NPs such as gold NPs, quantum dots, and iron oxide nanoparticles with fDNA, we designed stimuli-responsive fDNA-NPs that exhibit target induced assembly and disassembly of NPs, resulting in a variety of colorimetric, fluorescent, and magnetic resonance imaging (MRI)-based sensors for diagnostic of a broad range of analytes. To impart both biocompatibility and selectivity on inorganic NPs for targeted bioimaging, we have demonstrated DNA-mediated surface functionalization, shape-controlled synthesis, and coordinative assembly of such NPs as specific bioprobes. A highlight is provided on the construction of fDNA-based nanoprobes with light-activatable sensing and imaging functions, which provides precise control of recognition properties of fDNA with high spatiotemporal resolution. To explore the potential of organic NPs for biosensing applications, we have developed an enzyme-responsive fDNA-liposome as a universal sensing platform compatible with diverse biological targets as well as different detection methods including fluorescence, MRI, or temperature, making possible point-of-care diagnostics. To expand the application regime of organic NPs, we collaborated with the Zimmerman group to prepare single-chain block copolymer-based NPs and incorporated it with a variety of functions, including monovalent DNA for assembly, tunable surface chemistry for cellular imaging, and coordinative Cu(II) sites for catalyzing intracellular click reactions, demonstrating the potential of using organic NPs to create promising fDNA-NP systems with programmable functionalities. Furthermore, we survey our recent endeavor in integration of cell-specific aptamers with different NPs for targeted drug delivery, showing that introducing stimuli-responsive properties into NPs that target tumor microenvironments would enable safer and more effective therapy for cancers. Finally, current challenges and future perspectives in fDNA-mediated engineering of NPs for biomedical applications are discussed.
Identifiants
pubmed: 31411853
doi: 10.1021/acs.accounts.9b00167
pmc: PMC7103426
mid: NIHMS1576820
doi:
Substances chimiques
DNA
9007-49-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2415-2426Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM124316
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH110975
Pays : United States
Références
Chem Rev. 2005 Apr;105(4):1547-62
pubmed: 15826019
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4564-9
pubmed: 25831510
J Am Chem Soc. 2013 Apr 10;135(14):5254-7
pubmed: 23531046
Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7955-9
pubmed: 17094149
Angew Chem Int Ed Engl. 2014 May 26;53(22):5573-7
pubmed: 24740625
Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6121-5
pubmed: 22566291
Chem Commun (Camb). 2013 Jul 4;49(52):5823-5
pubmed: 23589821
Nature. 2010 Feb 25;463(7284):1061-5
pubmed: 20182508
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Angew Chem Int Ed Engl. 2017 Jun 6;56(24):6798-6802
pubmed: 28471018
Angew Chem Int Ed Engl. 2012 Sep 3;51(36):9078-82
pubmed: 22865657
ACS Nano. 2015 Oct 27;9(10):10227-36
pubmed: 26327513
Nat Chem. 2011 Jul 24;3(9):697-703
pubmed: 21860458
J Am Chem Soc. 2017 Mar 15;139(10):3623-3626
pubmed: 28263067
Proc Natl Acad Sci U S A. 2015 May 12;112(19):5903-8
pubmed: 25918425
Adv Drug Deliv Rev. 2008 Aug 17;60(11):1278-88
pubmed: 18514969
ACS Nano. 2012 May 22;6(5):3974-81
pubmed: 22424140
J Am Chem Soc. 2008 Oct 29;130(43):14217-26
pubmed: 18837498
Theranostics. 2016 Jun 15;6(9):1336-52
pubmed: 27375783
Chembiochem. 2016 Jun 16;17(12):1111-7
pubmed: 27123758
Chembiochem. 2007 Sep 24;8(14):1675-8
pubmed: 17696177
J Am Chem Soc. 2017 Oct 4;139(39):13804-13810
pubmed: 28899098
Angew Chem Int Ed Engl. 2015 Jul 6;54(28):8114-8
pubmed: 26096755
Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2056-61
pubmed: 17284609
J Am Chem Soc. 2016 Dec 21;138(50):16542-16548
pubmed: 27935691
Nat Biomed Eng. 2017;1:644-653
pubmed: 29152410
Nano Lett. 2010 May 12;10(5):1886-91
pubmed: 20405820
Anal Chem. 2007 Jun 1;79(11):4120-5
pubmed: 17477504
Nat Nanotechnol. 2009 Feb;4(2):121-5
pubmed: 19197315
Angew Chem Int Ed Engl. 2009;48(35):6494-8
pubmed: 19623590
Curr Opin Biotechnol. 2017 Jun;45:191-201
pubmed: 28458112
Chem Sci. 2018 Mar 7;9(16):3906-3910
pubmed: 29780521
J Am Chem Soc. 2018 Dec 19;140(50):17656-17665
pubmed: 30427666
Chem Rev. 2015 Oct 14;115(19):10725-815
pubmed: 26151155
J Am Chem Soc. 2013 Feb 20;135(7):2411-4
pubmed: 23356394
J Am Chem Soc. 2007 Jul 11;129(27):8634-43
pubmed: 17567134
Chem Rev. 2016 Mar 9;116(5):2826-85
pubmed: 26799741
Angew Chem Int Ed Engl. 2014 Dec 8;53(50):13798-802
pubmed: 25314680
J Am Chem Soc. 2016 Sep 7;138(35):11077-80
pubmed: 27529791
Neoplasia. 2015 Aug;17(8):661-70
pubmed: 26408258
Bioconjug Chem. 2008 Feb;19(2):412-7
pubmed: 18173225
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415
Chem Rev. 2009 May;109(5):1948-98
pubmed: 19301873
Chem Commun (Camb). 2010 Mar 7;46(9):1416-8
pubmed: 20162133
J Am Chem Soc. 2014 Oct 29;136(43):15195-202
pubmed: 25243485
J Mater Chem B. 2013 Oct 21;1(39):5288-5297
pubmed: 24159374
Angew Chem Int Ed Engl. 2005 Dec 16;45(1):90-4
pubmed: 16292781
Angew Chem Int Ed Engl. 2010 Feb 1;49(6):1052-6
pubmed: 20084650
Anal Chem. 2016 Feb 2;88(3):1506-10
pubmed: 26750765
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):4340-4344
pubmed: 29632214
J Am Chem Soc. 2003 Jun 4;125(22):6642-3
pubmed: 12769568
Chem Soc Rev. 2012 Apr 7;41(7):2740-79
pubmed: 22109657
Acc Chem Res. 2014 Jun 17;47(6):1881-90
pubmed: 24871359
J Am Chem Soc. 2015 Apr 29;137(16):5272-5
pubmed: 25853565
Curr Opin Colloid Interface Sci. 2018 Nov;38:158-169
pubmed: 31289450
Am J Clin Pathol. 2010 Oct;134(4):529-31
pubmed: 20855632
Nat Rev Drug Discov. 2017 Mar;16(3):181-202
pubmed: 27807347
Chem Rev. 2015 Jan 14;115(1):395-465
pubmed: 25492128
J Am Chem Soc. 2018 Jan 17;140(2):578-581
pubmed: 29281270
Adv Healthc Mater. 2012 Sep;1(5):567-72
pubmed: 23184791
Adv Mater. 2019 Nov;31(45):e1804745
pubmed: 30276873
Chem Rev. 2013 Apr 10;113(4):2842-62
pubmed: 23509854